期刊
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
卷 4, 期 1, 页码 46-52出版社
WILEY
DOI: 10.1002/acn3.377
关键词
-
资金
- US National Multiple Sclerosis Society [RG4856]
- NIH/NINDS [K02NS072288, R01NS092835, R01NS026799, R01NS049477]
- Gottfried and Julia Bangerter-Rhyner Foundation
- Freiwillige Akademische Gesellschaft (Basel, Switzerland)
A patient with relapsing multiple sclerosis (RMS) was treated with a standard immunomodulatory therapy, but due to ongoing disease activity was switched to rituximab. Relapses ceased, but secondary progressive MS (SPMS) eventually appeared, associated with new focal spinal cord white matter lesions. Cerebrospinal fluid (CSF) showed persistent oligoclonal bands (OCB) and clonally related B cells in CSF and peripheral blood. The treatment escalation approach failed to prevent evolution to SPMS, raising the question of whether initiation of B-cell depleting therapy at the time of RMS diagnosis should be tested to more effectively address the immune pathology leading to SPMS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据